Glancy Prongay & Murray LLP (“GPM”) announces an investigation on behalf of investors of Lipocine Inc. (“Lipocine” or the “Company”) (NASDAQ: LPCN) concerning the Company and its officers’ possible violations of federal securities laws. GPM is preparing a lawsuit on behalf of injured investors.

Lipocine is a specialty pharmaceutical company that develops pharmaceutical products using its oral drug delivery technology in the areas of men’s and women’s health.

On June 29, 2016, Lipocine disclosed that it received a Complete Response Letter (“CRL”) from the United States Food and Drug Administration (“FDA”) concerning its New Drug Application (“NDA”) for LPCN 1021, a drug candidate for testosterone replacement therapy ("TRT"). In the CRL, the FDA identified deficiencies related to the dosing algorithm for the label and informed the Company that an application could not be approved in its present form.

On this news, shares of Lipocine have fallen sharply, over 51% to just $3.01 per share during intra-day trading on June 29, 2016.

If you purchased Lipocine securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy, Esquire, of GPM, 1925 Century Park East, Suite 2100, Los Angeles, California 90067 at 310-201-9150, Toll-Free at 888-773-9224, by email to shareholders@glancylaw.com, or visit our website at http://www.glancylaw.com. If you inquire by email please include your mailing address, telephone number and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.